The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.
Open accessAbstract
In the National Heart, Lung and Blood Institute Type II Coronary Intervention Study, patients with Type II hyperlipoproteinemia and coronary artery disease (CAD) were placed on a low-fat, low-cholesterol diet and then were randomly allocated to receive either 6 g cholestyramine four times daily or placebo. This double-blind study evaluated the effects of cholestyramine on the progression of CAD as assessed by angiography. Diet alone reduced the low-density lipoprotein cholesterol 6% in both groups. After randomization, low-density lipoprotein cholesterol decreased another 5% in the placebo group and 26% in the cholestyramine-treated group. Coronary angiography was performed in 116 patients before and after 5 years of treatment. CAD progressed in 49% (28 of 57) of the placebo-treated patients vs 32% (19 of 59) of the cholestyramine-treated patients (p less than .05). When only definite progression was considered, 35% (20 of 57) of the placebo-treated patients vs 25% (15 of 59) of the cholestyramine-treated patients exhibited definite progression; the difference was not statistically significant. However, when this analysis was performed with adjustment for baseline inequalities of risk factors, effect of treatment was more pronounced. Of lesions causing 50% or greater stenosis at baseline, 33% of placebo-treated and 12% of cholestyramine-treated patients manifested lesion progression (p less than .05). Similar analyses with other end points (percent of baseline lesions that progressed, lesions that progressed to occlusion, lesions that regressed, size of lesion change, and all cardiovascular end points) all favored the cholestyramine-treated group, but were not statistically significant. Thus, although the sample size does not allow a definitive conclusion to be drawn, this study suggests that cholestyramine treatment retards the rate of progression of CAD in patients with Type II hyperlipoproteinemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,346
KANNEL, W. B., CASTELLI, W. P., & GORDON, T. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-85 · Cited by 1,311
Reversal of advanced atherosclerosis in Rhesus monkeys
Vesselinovitch, D., Wissler, R. W., Hughes, R., et al. (1976) · Atherosclerosis · doi:10.1016/0021-9150(76)90092-7 · Cited by 127
A study of atherosclerosis regression in Macaca mulatta
Clarkson, T. B., Lehner, N. D. M., Wagner, W. D., Clair, R. W. S., Bond, M. G., & Bullock, B. C. (1979) · Experimental and Molecular Pathology · doi:10.1016/0014-4800(79)90090-x · Cited by 110
Cholestyramine in Type II Hyperlipoproteinemia
Levy, R. I., FREDRICKSON, D. S., STONE, N. J., BILHEIMER, D. W., BROWN, W. V., GLUECK, C. J., Gotto, A. M., HERBERT, P. N., KWITEROVICH, P. O., LANGER, T., et al. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-51 · Cited by 99
Self-citationDietary Management of Hyperlipoproteinemia1
Levy, R. I., BONNELL, M., & Ernst, N. D. (1971) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(21)13832-5 · Cited by 83
Self-citationBrensike, J. F., Kelsey, S. F., Passamani, E. R., Fisher, M. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., Moriarty, D. J., et al. (1982) · Controlled Clinical Trials · doi:10.1016/0197-2456(82)90038-1 · Cited by 45
Self-citationReliability of assessing change with sequential coronary angiography
Detre, K. M., Kelsey, S. F., Passamani, E. R., et al. (1982) · American Heart Journal · doi:10.1016/0002-8703(82)90017-5 · Cited by 40
Self-citation
Cited by
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Munoz (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6269 · Cited by 760
Metadata
- Authors
- Brensike, J. F., Levy, R. I., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., & Moriarty, D. J.
- Venue
- Circulation
- Published
- 1984-02
- Volume
- 69
- Issue
- 2
- Pages
- 313-324
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2053235682
- Cited by
- 668
- References
- 10
- FWCI
- 48.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. https://app.cochat.ai/papers/10.1161/01.cir.69.2.313
- The paper
- Brensike, J. F., Levy, R. I., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., & Moriarty, D. J. (1984). Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. https://doi.org/10.1161/01.cir.69.2.313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
